Description and Brand Names

Drug information provided by: Merative, Micromedex®

US Brand Name

  1. Anucort-HC
  2. Anu-Med HC
  3. Anusol HC
  4. Anusol-HC
  5. Anuzone-HC
  6. Colocort
  7. Cortifoam
  8. Encort
  9. GRx HiCort 25
  10. Hemril-30
  11. Hemril-HC Uniserts
  12. Proctocort
  13. Procto-Kit 1
  14. Procto-Kit 25
  15. Proctosert HC
  16. Proctosol-HC
  17. Proctozone-HC
  18. Rectacort-HC
  19. Rectasol-Hc
  20. Uceris

Canadian Brand Name

  1. Cortiment-10
  2. Cortiment-40
  3. Rectocort

Descriptions


Rectal corticosteroids are used to treat mild or moderate ulcerative colitis. They also may be used along with systemic (oral or injection) corticosteroids or other medicines to treat severe disease or mild to moderate disease that has spread too far to be treated effectively by medicine inserted into the rectum alone. Rectal corticosteroids also are used to help relieve swelling, itching, and discomfort of some other rectal problems, including hemorrhoids and inflammation of the rectum caused by radiation therapy.

Rectal corticosteroids are available only with your doctor's prescription.

This product is available in the following dosage forms:

  • Foam
  • Cream
  • Enema
  • Suppository

From Mayo Clinic to your inbox

Sign up for free and stay up to date on research advancements, health tips, current health topics, and expertise on managing health. Click here for an email preview.

To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you. If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail.

Portions of this document last updated: Feb. 01, 2023